Abstract
Angiogenesis is a hallmark of malignant transformation. With improved understanding of angiogenic signaling in both the normal and malignant state, there have been a number of agents developed that target VEGF signaling. These targeted agents can affect downstream VEGF signal transduction via unique mechanisms at different cellular and extracellular locations. The aflibercept, or VEGF-Trap, molecule is the subject of this article. Its molecular structure, pharmacokinetic and pharmacodynamic profile, and preclinical and early clinical data in epithelial ovarian carcinoma is reviewed. For comparison, other anti-angiogenic agents that have been or are currently being studied in epithelial ovarian carcinoma are also summarized. Finally, the anticipated role of aflibercept in the treatment of epithelial ovarian carcinoma is also discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 591-600 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2009 |
Keywords
- Aflibercept
- Antiangiogenesis
- Epithelial ovarian carcinoma
- VEGF-Trap
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Oncology
- Cancer Research